Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
Scott DN, Palmer MA, Tidhar MT, Stoove PM, Sacks-Davis DRS, Doyle AJS, Pedrana DAJ, Thompson PA, Wilson PDP, Hellard PM
The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioid-related deaths: findings from a modelling study.
Nielsen S, Scott N, Tidhar T, Quiroga MDM, Lenton S, Dietze P
Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG, Scott N, Walker JG, Hamid S, Hellard M, Vickerman P
Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, Thursz MR, Brown AS, Hellard M, Lemoine M
Psychiatric well-being among men leaving prison reporting a history of injecting drug use: A longitudinal analysis.
Stewart AC, Cossar R, Lee Wilkinson A, Scott N, Dietze P, Quinn B, Kinner SA, Aitken C, Walker S, Curtis M, Butler T, Ogloff JRP, Stoové M
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N, on the EC Partnership